Breast Cancer | Specialty

The OncLive Breast Cancer condition center page is a comprehensive resource for clinical news and expert insights on various types of breast cancer, including those that are triple negative, hormone receptor positive, and/or HER2 positive. This page features news articles, interviews in written and video format, and podcasts that focus on treatment advances and ongoing research in breast cancer.

Miami Breast Keynotes Highlight the Call to Action for Advocacy Efforts in Breast Cancer

March 4th 2023

Lindsay Avner Kaplan and Nancy G. Brinker, the keynote speakers of the 40th Annual Miami Breast Cancer Conference, discuss the need to confront social determinants of health for patients and drive the public conversation and interpretation of personal and clinical stories in health care.

Treatment in HR+ Early Breast Cancer May be Best Guided by Risk of Recurrence

March 4th 2023

After settling the debate of which patients with early-stage, hormone receptor–positive breast cancer require chemotherapy in addition to endocrine therapy, investigators have set their sights on determining whether ovarian function suppression can deliver the same effects of chemotherapy and when to recommend abemaciclib and olaparib.

SERMS, SERDS, and PROTEC Are Poised to Shake Up Treatments for ER+ Breast Cancer

March 4th 2023

Novel selective estrogen receptor modulators, selective estrogen receptor degraders, and proteolysis-targeting chimera inhibitors have demonstrated early efficacy for patients with breast cancer who experience disease progression following CDK4/6 inhibitor treatment.

Progress in Treating Brain Metastases in Breast Cancer Puts Multidisciplinary Approaches Into Focus

March 4th 2023

Brain metastases are a common complication in patients with breast cancer, and although systemic therapies for patients with HER2-positive disease have displayed promise in penetration of the blood-brain barrier, work remains for subsets of patients with central nervous system metastases.

Artificial Intelligence, MRI, and Interdisciplinary Collaboration Topics Draw Radiologists, Surgeons to Miami

March 4th 2023

The growth of artificial intelligence allows physicians to see tumors in unprecedented ways.

I-SPY 2 Framework Could Represent the Future of Drug Development in Breast Cancer

March 3rd 2023

By moving away from adjuvant- to neoadjuvant-based protocols, such as I-SPY, investigators may be better able to develop effective treatments for patients in less time by refining the understanding of who will benefit from therapy, enabling strategies with multiple pathway targets, and testing approaches earlier in the disease course.

ADC Developments in HER2– Breast Cancer Treatment Shake Up Paradigm

March 3rd 2023

As additional antibody-drug conjugates continue to emerge for the treatment of patients with HER2-negative breast cancer, identifying optimal sequencing strategies and managing toxicities associated with these agents remain top priorities for their use, according to Hope S. Rugo, MD.

Dr. Hunt on Axillary Reverse Mapping in Breast Cancer

March 3rd 2023

Kelly K. Hunt, MD, FACS, FSSO, discusses technical considerations for axillary reverse mapping in breast cancer for the reduction or prevention of lymphedema.

FDA Expands Abemaciclib Indication in HR+/HER2–, Node+, High-Risk Breast Cancer

March 3rd 2023

The FDA approved an expanded indication for abemaciclib (Verzenio) in combination with endocrine therapy for the adjuvant treatment of adult patients with hormone receptor–positive, HER2-negative, node-positive, early breast cancer that is at a high risk of recurrence.

Predictive, Prognostic Models May Tailor Neoadjuvant Approach in HER2+ Breast Cancer

March 3rd 2023

With the advent of effective drug regimens to treat HER2-positive breast cancer, the use of tailored efforts with neoadjuvant therapy in this space may continue to improve efficacy moving forward.

HER2-Low Expression is the Tip of the Iceberg in Breast Cancer Classification

March 3rd 2023

The advent of antibody-drug conjugates has placed a renewed focus on the lesser thought of HER2 classifications of IHC 1+ and 0.

Pilewskie Highlights Trends for Surgical Management of High-risk Breast Lesions

March 3rd 2023

Melissa L. Pilewskie, MD, highlightes some of the primary components of her presentation concerning high-risk breast lesions, which will be delivered during the 40th Annual Miami Breast Cancer Conference®

Dr. Esserman on the I-SPY2 Trial in Breast Cancer

March 3rd 2023

Laura J. Esserman, MD, MBA, discusses the rationale and design for the phase 2 I-SPY2 trial.

Miami Breast Cancer Conference Celebrates 40 Years

March 3rd 2023

The agenda set for this year's Miami Breast Cancer Conference® has been shaped by the recent updates out of the 2022 San Antonio Breast Cancer Symposium, updates to guideline recommendations over the past year, and the influence of new indications and approvals across subtypes of breast cancer.

Emerging Concepts in mBC Treatment

March 2nd 2023

Paolo Tarantino, MD, highlights additional abstracts from SABCS 2022 that he found particularly interesting.

Investigational ADCs for Treatment of TNBC

March 2nd 2023

Komal Jhaveri, MD, FACP, explains the potential role ADCs may have in the future of breast cancer treatment.

Continuing CDK4/6 Inhibition at Progression of HR+ Metastatic Breast Cancer

March 2nd 2023

Key opinion leaders consider when it is appropriate to continue CDK4/6 inhibition at progression of disease in the setting of HR+ metastatic breast cancer.

Molecular Testing in Relapsed/Refractory HR+ Metastatic Breast Cancer

March 2nd 2023

A brief review of the role molecular profiling plays at a patient’s relapse with HR+ metastatic breast cancer.

Potential Role for T-DXd in Early-Stage HER2-Low Breast Cancer

February 28th 2023

Panelists share a brief discussion on early-stage HER2-low breast cancer and identify treatment options available in that setting.

Optimizing Real-World Management of HER2-Low Breast Cancer

February 28th 2023

Comprehensive insight on evolving management strategies for patients diagnosed with HER2-low breast cancer.